Slide 1: Introduction and Welcome
Introduction and Welcome Why preliminary results CEO out of country next week - Agenda -Fiscal year 2006 summary -Strategy going forward -Guidance going forward - Questions and Answers
Slide 2: Fiscal year 2006 Summary
Fiscal year 2006 Summary - Gross revenues = $5.855 MM (up 23%) - SG&A = $2.97 MM - R&D = $0.45 MM Income Before Income Taxes = $0.89 MM - Net Earnings = $0.68 MM ($0.083/share) (up 156%) - Cash flow = ($69,000) - after spending about $800,000 on acquisitions - so most the cash was recovered during t
Slide 3: Progress - ADMET Modeler
Progress - - ADMET Modeler Predictor/ADMET Modeler - - Merged into single program - New model to predict binding affinity of potential new drug molecules to HIV integrase to be released soon - Method for rapid calculation of a certain type of electrical charge developed charge developed - speed redu
Slide 4: ClassPharmer and DDDPlus
Progress - 2 ClassPharmer - -Acquired as version 3.5 - slow, limited - slow, limited - Merged ClassPharmer and ChemTK to produce ClassPharmer 4.0 - Dramatic speed increase Able to handle much larger number of molecules Version 4.1 released in ____, Version 4.2 will release soon - Very successful fir
Slide 5: GastroPlus
Progress - 3 - GastroPlus - - Flagship product and biggest money maker -- Becoming a standard part of studies in several major pharmaceutical companies - pharmaceutical companies - Released version 5.0 in December 2005 added physiologically based pharmacokinetics (PBPK) modeling - Particle size dist
Slide 6: Words+ subsidiary
Progress - 4 - Words+ subsidiary Added consulting marketing and sales manager - Expanded U.S. sales force - SAM software migrated to PC SAM software migrated to PC’s from PDA Improved MicroCommPac (part of almost every (part of almost every system) - New laptop provides improved margins on Medicare/
Slide 7: Strategy Going Forward
Strategy Going Forward Expand product line and services - - Pharmaceutical software - New functionalities for current products Completion of MembranePlus™ - Seeking opportunities to partner or acquire new products - - Pharmaceutical consulting services - Expanding Simulation Technologies team to han
Slide 8: Summary
Summary - Company is strong and growing - No debt -Strong cash flow and consistent growth in shareholders’ equity demonstrates real growth Cash spent on acquisitions was substantially replaced in one year Growing dedicated and extremely talented workforce working to grow the product lines in both bu
Slide 9: Questions?
Questions? nee